Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarah Cannon Research

Neither a doctor nor a teaching hospital

Research payments

$19,388,985

4,219 payments

Through program year 2025, Sarah Cannon Research is reported as receiving $19,388,985 in research payments, across 4,219 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,784,049 1,026
2024 Research $406,241 174
2023 Research $1,245,478 75
2022 Research $4,771,867 877
2021 Research $4,819,046 1,001
2020 Research $1,936,937 457
2019 Research $3,425,367 609

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $5,819,980 1,099 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $3,339,893 612 payments
  3. Pfizer Inc. $2,092,853 597 payments
  4. Exelixis Inc. $1,847,749 763 payments
  5. AstraZeneca Pharmaceuticals LP $1,482,116 84 payments
  6. Array BioPharma Inc. $1,291,350 424 payments
  7. Regeneron Pharmaceuticals, Inc. $912,510 120 payments
  8. GlaxoSmithKline, LLC. $810,650 204 payments
  9. F. Hoffmann-La Roche AG $794,283 100 payments
  10. Moderna TX, Inc. $306,149 85 payments
Studies the money was for Research payments · program years 2019–2025
  1. Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL $1,736,240 141 payments
  2. PH III Open Label Study Atezo VS BSC Following Adjuvant Chemo in Stage Ib Iiia Nsclc $1,329,797 228 payments
  3. A First-In-Human Study of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody to Programmed Death - 1 PD 1, As Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies $912,510 120 payments
  4. A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine As First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Or Low-Blast Acute Myelogenous Leukemia $855,872 181 payments
  5. A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (Idd) in Relapsed And/Or Refractory Multiple Myeloma (RRMM) $696,238 82 payments
  6. A Phase 2 Openlabel Study of Encorafenib Binimetinib in Patients With Brafv600mutant Nonsmall Cell Lung Cancer $685,127 218 payments
  7. PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc $591,378 96 payments
  8. 1L Nsclc Non Squamous DX All Comer Abraxane $564,041 53 payments
  9. A Phase 1B2 Openlabel Study to Evaluate Safety Clinical Activity Pharmacokinetics and Pharmacodynamics of Avelumab Msb0010718c in Combination With Other Cancer Immunotherapies in Patients With Advanced Malignancies $537,110 116 payments
  10. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors $520,258 342 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record